Literature DB >> 1285495

Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.

J M Schröder1, M Bertram, R Schnabel, U Pfaff.   

Abstract

Zidovudine (formerly azidothymidine) is a potent inhibitor of the human immunodeficiency virus (HIV) reverse transcriptase and represents the first approved drug showing clinical efficacy in HIV-associated diseases. However, considerable toxicity causing macrocytic anemia, neutropenia, and myopathy has been reported, with severe mitochondrial alterations as a special feature of this myopathy. The mitochondrial changes are consistent with the fact that zidovudine acts as an inhibitor of the mitochondrial gamma-polymerase. Electron microscopically, we could confirm the presence of severely altered mitochondria in a 32-year-old male, who developed a necrotizing myopathy after daily administration of 1,000 mg zidovudine over a period of 15 months. In addition, there were even more severe nuclear changes that, for the most part, have not been documented electron microscopically in HIV-related myopathy either with or without zidovudine treatment, especially in non-necrotic and non-regenerating fibers. Since various in vitro studies have shown interference of zidovudine with nuclear DNA metabolism even in human cell lines, we assume that the nuclear changes that we observed are at least in part related to zidovudine treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1285495     DOI: 10.1007/bf00304632

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  62 in total

1.  HTLV-I polymyositis in a patient also infected with the human immunodeficiency virus.

Authors:  C A Wiley; M Nerenberg; D Cros; M C Soto-Aguilar
Journal:  N Engl J Med       Date:  1989-04-13       Impact factor: 91.245

2.  Muscle damage induced by isotretinoin.

Authors:  E Hodak; N Gadoth; M David; M Sandbank
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16

3.  Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM).

Authors:  V I Avramis; W Markson; R L Jackson; E Gomperts
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

4.  Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment.

Authors:  P K Panegyres; J M Papadimitriou; P N Hollingsworth; J A Armstrong; B A Kakulas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

5.  Myopathy complicating the acquired immune deficiency syndrome.

Authors:  R Stern; J Gold; E F DiCarlo
Journal:  Muscle Nerve       Date:  1987-05       Impact factor: 3.217

6.  Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction.

Authors:  C Mhiri; M Baudrimont; G Bonne; C Geny; F Degoul; C Marsac; E Roullet; R Gherardi
Journal:  Ann Neurol       Date:  1991-06       Impact factor: 10.422

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  D-penicillamine-induced polymyositis in patients with rheumatoid arthritis.

Authors:  K Takahashi; T Ogita; H Okudaira; S Yoshinoya; H Yoshizawa; T Miyamoto
Journal:  Arthritis Rheum       Date:  1986-04

9.  Granular nuclear inclusion body disease: fine structure of tibial muscle and sural nerve.

Authors:  J M Schröder; K G Krämer; H C Hopf
Journal:  Muscle Nerve       Date:  1985-01       Impact factor: 3.217

10.  Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients.

Authors:  W D Snider; D M Simpson; S Nielsen; J W Gold; C E Metroka; J B Posner
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

View more
  6 in total

Review 1.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

2.  Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.

Authors:  E J Cupler; M J Danon; C Jay; K Hench; M Ropka; M C Dalakas
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

3.  Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy.

Authors:  S Morgello; D Wolfe; E Godfrey; R Feinstein; M Tagliati; D M Simpson
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  AZT-induced oxidative cardiovascular toxicity: attenuation by Mg-supplementation.

Authors:  I Tong Mak; Joanna J Chmielinska; Jay H Kramer; William B Weglicki
Journal:  Cardiovasc Toxicol       Date:  2009-05-12       Impact factor: 3.231

5.  Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2',3'-dideoxycytidine.

Authors:  D Feldman; T D Anderson
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy.

Authors:  M Tolomeo; S Mancuso; M Todaro; G Stassi; M Catalano; S Arista; G Cannizzo; E Barbusca; V Abbadessa
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.